Caplin Point Laboratories has informed that it enclosed a Press Release regarding grant of final approval by the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Norepinephrine Bitartrate Injection USP, to its Subsidiary Caplin Steriles.
The above information is a part of company’s filings submitted to BSE.